Pharmosa Biopharm Inc. (TPEX:6875)
36.50
+0.20 (0.55%)
Jun 18, 2026, 1:30 PM CST
Pharmosa Biopharm Revenue
Pharmosa Biopharm had revenue of 1.79M TWD in the quarter ending March 31, 2026. This brings the company's revenue in the last twelve months to 69.06M, down -58.77% year-over-year. In the year 2025, Pharmosa Biopharm had annual revenue of 67.27M, down -59.86%.
Revenue (ttm)
69.06M
Revenue Growth
-58.77%
P/S Ratio
68.28
Revenue / Employee
n/a
Employees
40
Market Cap
4.72B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 67.27M | -100.30M | -59.86% |
| Dec 31, 2024 | 167.57M | -146.93M | -46.72% |
| Dec 31, 2023 | 314.50M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Panion & Bf Biotech | 2.10B |
| Medigen Biotechnology | 1.34B |
| Mycenax Biotech | 815.34M |
| Formosa Pharmaceuticals | 54.32M |
| OBI Pharma | 49.68M |
| UnicoCell Biomed | 26.54M |
| AnnJi Pharmaceutical | 7.55M |
| Senhwa Biosciences | 1.06M |